Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Soleno Therapeutics, Inc. (“Soleno”) fell over 12% on September 10, 2025, after the company disclosed a patient death involving its treatment for Prader-Willi Syndrome, VYKAT XR. Previously, on Friday, August 15, 2025, Soleno stock dropped more than 8% after Scorpion Capital released a report alleging that VYKAT XR poses serious safety concerns and is potentially at risk of being withdrawn from the market. Gibbs Mura is investigating a potential Soleno Therapeutics, Inc. (NASDAQ: SLNO) Securities Class Action Lawsuit concerning whether Soleno has violated federal securities laws by providing false or misleading statements to investors.

IF YOU INVESTED IN SLNO, VISIT OUR SOLENO LAWSUIT INVESTIGATION WEBPAGE OR CALL US AT [phone] TO GET MORE INFORMATION ABOUT HOW YOU MAY BE ABLE TO RECOVER YOUR LOSSES.

What is the Soleno Lawsuit Investigation About?

On August 15, 2025, Scorpion Capital released a 415-page report alleging that Soleno’s recently approved treatment for Prader-Willi syndrome, VYKAT XR, poses serious safety concerns and is potentially at risk of being withdrawn from the market. The report cites a “rapid pile-up of reports of children hospitalized for potential heart failure in recent weeks, shortly after starting VYKAT XR.”

Additionally, Scorpion Capital claims that Soleno’s “hocus-pocus” launch metrics obscure the company’s dependence on a controversial Florida physician that has a “pattern of association with questionable [Prader-Willi Syndrome] therapies.”

Finally, Scorpion Capital claims that “Soleno’s clinical trials were a sham that make a mockery of the scientific method,” specifically citing a withdrawal study that “exhibits red flags for suspect data/results,” along with comments from ex-employees and others expressing concern about the company’s alleged trial practices.

Following the report, shares of Soleno fell over 8% on August 15, 2025, causing harm to investors.

Then, on September 10, 2025, Soleno disclosed a patient death involving its Prader-Will Syndrome treatment, VYKAT XR, which was reported in the FDA’s Adverse Event Reporting System. Following this news, shares of Soleno fell over 12% on September 10, 2025, causing further harm to investors.

About Gibbs Mura, A Law Group

Gibbs Mura represents investors nationwide in securities litigation. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.